Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences reports developments as a late-stage biopharmaceutical company focused on novel therapies for neurological disorders with significant unmet medical need. Its recurring news centers on tralesinidase alfa enzyme replacement therapy, or TA-ERT, for Sanfilippo Syndrome Type B (MPS IIIB), including clinical data presentations, FDA interactions and regulatory planning for the program.
Company updates also cover financial results, capital actions involving common stock and pre-funded warrants, investor conference participation, and additions to commercial leadership as Spruce builds capabilities around a potential rare-disease launch.
Spruce Biosciences (Nasdaq: SPRB), a late-stage biopharmaceutical company specializing in novel therapies for endocrine and neurological disorders, has announced its participation in the Guggenheim Securities Healthcare Innovation Conference. The company's CEO, Javier Szwarcberg, M.D., M.P.H., will deliver a presentation on November 11, 2024, at 3:30 p.m. ET. The presentation will be accessible via live webcast, with a recording available on the company's investor relations website for approximately 90 days following the event.
Spruce Biosciences (Nasdaq: SPRB), a late-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's CEO, Javier Szwarcberg, M.D., M.P.H., is scheduled to present on September 10, 2024, at 4:30 p.m. ET.
Spruce Biosciences focuses on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical needs. Interested parties can access the live webcast of the presentation through a provided link. An archived version of the webcast will be available on the company's investor relations website for approximately 90 days after the event.
Spruce Biosciences (SPRB) reported Q2 2024 financial results and provided corporate updates. Key highlights include:
1. Strategic collaboration with HMNC Brain Health to develop tildacerfont for Major Depressive Disorder (MDD).
2. Topline data from CAHmelia-204 and CAHptain-205 studies of tildacerfont in Congenital Adrenal Hyperplasia (CAH) expected in Q4 2024.
3. Cash runway through the end of 2025 with $69.7 million in cash and cash equivalents as of June 30, 2024.
4. Q2 2024 financial results: Collaboration revenue of $1.6 million, R&D expenses of $8.1 million, G&A expenses of $3.6 million, and net loss of $9.2 million.
5. Anticipated End of Phase 2 meeting with FDA in H1 2025.
Spruce Biosciences (Nasdaq: SPRB), a late-stage biopharmaceutical company, has been recognized as a Best Place to Work in 2024 by the San Francisco Business Times and Silicon Valley Business Journal. The accolade highlights Spruce's dedication to creating a mission-driven culture emphasizing trust, innovation, ownership, and diversity. CEO Javier Szwarcberg expressed pride in the employees' commitment, which underpins the company's efforts to develop therapies for endocrine and neurological disorders. The award was based on anonymous employee surveys from over 230 companies, evaluating factors such as collaborative culture, benefits, and management practices.
Spruce Biosciences (Nasdaq: SPRB) and HMNC Brain Health announced a strategic collaboration to develop a treatment for Major Depressive Disorder (MDD) using Spruce's tildacerfont and HMNC's Cortibon Genetic Selection Tool. The Phase 2 study is set to begin in Q4 2024. Should the study be successful, Spruce has the option to acquire exclusive rights to Cortibon. This collaboration aims to advance precision medicine in treating MDD, potentially addressing up to 50% of MDD patients worldwide. The collaboration leverages genetic markers to predict medication response, aiming to enhance treatment efficacy and reduce costs.
Spruce Biosciences presented positive results from its Phase 2 POWER study on tildacerfont, targeting polycystic ovary syndrome (PCOS), at ENDO 2024. Tildacerfont, a CRF1 receptor antagonist, significantly reduced DHEAS levels and increased SHBG levels versus placebo in women with elevated baseline DHEAS. These results suggest potential therapeutic benefits, including a reduction in health risks linked to hyperandrogenism. The study involved 27 women and showed that tildacerfont was well-tolerated with no serious adverse effects.
Spruce Biosciences, a late-stage biopharmaceutical company specializing in therapies for rare endocrine disorders, will participate in the Jefferies Global Healthcare Conference.
CEO Javier Szwarcberg will present on June 5, 2024, at 5:00 p.m. ET.
The presentation will be accessible via a live webcast, with an archived version available for 90 days on the company's investor relations website.
Spruce Biosciences (Nasdaq: SPRB) announced that three abstracts have been accepted for presentation at the 106th Annual Meeting of the Endocrine Society (ENDO 2024), taking place from June 1-4, 2024, in Boston.
The company will present final results from its Phase 2 POWER study of tildacerfont for the treatment of polycystic ovary syndrome (PCOS). Additionally, they will highlight comorbidities associated with congenital adrenal hyperplasia (CAH) and the importance of transitionary care between pediatric and adult endocrinology practices for CAH patients.
Spruce Biosciences (Nasdaq: SPRB), a biopharmaceutical company, reported its Q1 2024 financial results and provided corporate updates. Key highlights include a 45% reduction in ACTH in the CAHmelia-203 study, correlating higher baseline GC doses and drug compliance with better outcomes. The company anticipates topline data from CAHmelia-204 and CAHptain-205 in Q3 2024. Financially, Spruce reported $81.2 million in cash reserves, $2 million in collaboration revenue, and a net loss of $11.6 million, improving from $12.8 million YoY. R&D expenses decreased to $10.3 million, while G&A expenses rose to $4.3 million. Total operating expenses were $14.6 million, down from $15.2 million a year ago. Upcoming milestones include Phase 2 data and an FDA meeting in early 2025.
Spruce Biosciences, Inc. (Nasdaq: SPRB) will participate in two upcoming investor conferences in May, featuring Fireside chats and 1x1 meetings. The events will include the JMP Securities Life Sciences Conference on May 13-14, 2024, and the RBC Capital Markets Global Healthcare Conference on May 14-15, 2024. The CEO, Javier Szwarcberg, M.D., M.P.H., will be presenting at these conferences, with webcasts available on the company's investor relations website.